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ABSTRACT
Evolutionary theory of cancer was developed in 1976 by cancer research Peter Nowell and
has illuminated the path toward increasing safety and efficacy of clinical treatment strategies. Major
foundations that makeup the complexity in Darwinian framework of cancer includes clonal
evolution, clonal expansion, and competition. Due to these characteristics, virtually all types of
cancer have evolutionary capabilities to reject or adapt and become resistant to pharmaceutical
therapies. Despite compelling evidence of these process, evolutionary modeling of cancer continues
to be underutilized in clinical settings. Contributions to this include the complex adaptive
mechanisms that tools fail to detect or are unable to be targeted effectively, lack of studies regarding
quantity and relevance, and the perception of evolutionary theory. As a result, failure to clinically
adopt evolutionary modeling has delayed development of new cancer therapy strategies,
particularly for cancer recurrence. Drug resistance and relapse are devastating and compelling
pieces of evidence that should compel researchers and clinicians to integrate evolutionary modeling
into cancer treatment. Evolutionary modeling provides key insight into developing treatments that
are as dynamic as cancer biology, including personalized medicine, Adaptive
Therapy (AT), and to make systemic cancer treatments obsolete.
INTRODUCTION
Evolutionary theory of cancer defines neoplasms as tumors with abnormal growths of tissue
made up of genetically diverse population of trillions of cells that can accumulate selective
advantages from environmental pressures (Beerenwinkel, Greenman, Lagergren, 2016). Selective
advantages may result in tumor cell populations continuously competing and cooperating for
resources in the environment and can lead to adaptive drug resistant neoplasms (Merlo, Pepper,
Reid, & Maley, 2006). This ongoing cycle between clonal evolution, expansion, and competition is
what characterizes drug resistance and its ability to no longer respond to drug therapy, migrate to
other parts of the body, and become resistant once exposed to a therapy (Peters, 2018). Precursor
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cancer cells recognize antigens or other toxins and induces proliferation and differentiation into
various subclonal populations which evolve to promote drug resistance. (Polonsky, Chain, &
Friedman, 2016). Evolutionary modeling has provided a fundamental framework for neoplastic
progression and gives a look into the complex cycles of evolutionary processes which depend
largely on intratumor heterogeneity, yet clinical research remains static.
Clonal Evolution
Intratumor heterogeneity. Despite overwhelming evidence of evolutionary cancer biology,
clinical application for treatment and drug resistance remains uninvestigated and can be largely
attributed to intratumor heterogeneity. The adaptive nature of cancer is built off intratumor
heterogeneity, which is the intrinsic genetic diversity within all tumor cells that ultimately promotes
resistance or relapse (Thomas et al., 2012). Neoplastic cells will aggregate and generate clones that
will further differentiate into diverse subclonal populations. Researchers have shown that
stochastic, or random, variations in gene expression can increase the rate of adaptive evolution,
which may provide insight into cancer drug resistance. (Aktipis et al., 2011).
Mutation acquisition. Evolutionary theory profiles cancer as an opportunistic disease
driven by clonal evolution and expansion from accumulating selectively advantageous mutations
(Beerwinkel, Greenman, & Lagergren, 2016). Depicted in Fig. 1, branching of mutations arises from
genetic instability that leads to errors in gene duplication and differentiation (Turajlic, McGranahan,
& Swanton, 2015). The phylogenetic tree represents the derivation of mutations among clones and
allows researchers to identify common ancestors of tumors and the degree of relationship between
branches. Figure 1 provides a table of mutations and a phylogenetic branch of five clones (C1-5) and
are characterized by mutations (A-F) present. In one experiment, it was found that presence of
subclones were linked to poor clinical prognosis, increased risk of malignancy and relapse,
indicating progressive mutational branching. The chronology of mutation acquisition has provided
insight into metastases and bottlenecking (selective sweeps). Tracing genetically distinct subclones
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by generation back to its ancestor mutation may reveal history of tumor evolution and identify
possible biomarkers (Turajlic et al., 2015).

Figure 1. Acquisition and
branching process of mutation.
Mutations can be traced back to
ancestor to identify potential
biomarkers. (Turajlic,
McGranahan, & Swanton, 2015).

More specifically, evolutionary modeling has shed light onto tumor biopsy sampling using
multiregion sequencing of somatic mutation genes among a tumor, indicating ubiquitous (found in
every sample), shared (only among a few samples, and private (found only in one region of the
tumor) (Gerlinger et al., 2012). Fig. 2 depicts the phylogenetic relationships of the somatic
mutations according to their regional distribution in the tumor. The arrows indicate potential driver
mutations, that confer selective advantages. This study provides additional evidence of intratumor
heterogeneity and phylogenetic branching of mutations contributing to the difficulty in targeting
neoplasms and the consequences of biopsy samples from one region of a neoplasm. This study also
demonstrates multiregion sequencing of somatic mutations is necessary to create an accurate
representation of intratumor heterogeneity and develop clinical methods for predicting resistance
in neoplasms. By reconstructing the history of tumor progression, common or ubiquitous mutations
located in the trunk of the phylogenetic tree may contribute in identifying crucial biomarkers.
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Figure 2. Tumor heterogeneity and phylogeny. (A). Exome sequencing of regional
distribution of mutation (grey) and absent mutations (blue). (B). Phylogenetic
branching of somatic mutations (Gerlinger et al., 2012).
Natural selection. Researched suggested, that exposure to pharmaceutical therapies puts
selective pressures onto the population and can promote adaptation (Housman et al., 2014). As a
result, clonal evolution is the result of natural selection for the most fit cells in a neoplasm. This
concept is modeled in Fig. 3 and derives from the discovery of antibiotic resistance in bacteria which
suggests that while treatment eliminates weaker variations of the clonal population, surviving
clones are selected and will proliferate into a drug resistant tumor. Consequently, this illustrates the
combination of heterogeneous tumor cell populations and selective pressures against
pharmaceutical therapies offers a major cause to the challenge in reducing drug resistance in
cancer.
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Figure 3. General mechanism of
cancer resistance. An
evolutionary model that shows
cancer relapse as a product of
therapy that selects for resistant
cells among the heterogeneous
cell populations (Aktipis et al.,
2011).

Niches. Mutational sweeps are often the result of the elimination of weaker clones due to
anticancer agents and limited carrying capacity of the microenvironment, which is the tumors
distinct habitat as a part of the larger environment (Merlo et al., 2006). Fig 4A shows a diagram of
adaptive mutant sweeps that resulting in homogenization (fixation) of tissues and generation of
new, more diverse, clonal cells. The relationship between homogenization and clonal expansion is
modeled in Fig 4B, where genetic diversity fluctuates but also increases over time due to selective
sweeps over time. Similarly, Fig 4C depicts adaptive sweeps and homogenization within subclonal
populations. In contrast, Fig 4D graphical representation of subclonal genetic diversity over time
revealed no fluctuations because homogenization of tissue cannot overcome the increased size of
the tumor due to clonal expansion. Diversity in the neoplasm’s microenvironment will limit
adaptive sweeps to a specific subpopulation, resulting in a niche. Niches are tumor habitats specific
to distinct subpopulations that rely on unique resources to reduce competition and increase
expansion. This additional evidence supports why genetic diversity results in drug resistant tumors
or relapse and why we need more evolutionary models in clinical research.
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Figure 4(A). Adaptive mutant sweeps within a single population of cells that become fixed
representing in yellow, orange, and red, promoting clonal expansion from genetic diversity.
(B). Fluctuation of intratumor diversity over time along; increasing from genetic instability
of new clones and decreasing after the mutant selective sweep homogenizes the neoplasm.
(C). Adaptive mutant sweeps within clonal subpopulation (dashed lines). Selective sweeps
may become specified in diverse microenvironments (niches) and be constrained to one
subpopulation. (D). Tumor diversity gradually increasing because selective sweeps cannot
homogenize subpopulations (Merlo et al., 2006).
These studies offer evidence that intratumor heterogeneity comes from the accumulation of
genetic alterations and results in mutations of varying gene expression to increase rate of adaptive
evolution for drug resistance in tumors. Fig. 5 represents subclonal population propagating from
mutational selective sweeps and B shows the branching process of mutations as a mirror
representation of the subclonal structure (Beerwinkel, Greenman, & Lagergren, 2016). Modeling
tumor phylogeny by mutational branching may reveal valuable insight into neoplastic progression
and adaptive resistance to therapeutics. This model offers a simple conceptual tool for explaining
diverse subclonal populations and mutational branching, which may aid in the pursuit of clinical
research integration.
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Figure 5. Neoplastic progression and branching. A. Selective sweeps across phenotypically
normal tissue starting on the left and progressing over time to the right, generating new
subclonal populations. B. Mutational branching that mirrors the model of selective sweeps
(Beerenwinkel, Greenman, & Lagergren, 2016).
Clonal Expansion
Subclonal populations. Intratumor heterogeneity generates an ecosystem of subclonal
neoplasms that cooperate and compete with surrounding cells in the microenvironment (Bodi et al.,
2017). Differentiation in clonal expansion results in diverse subpopulations with varying degrees of
resistance upon which natural selection acts. In Fig. 6, composition of two simulated heterogenous
subclonal populations were examined in relation to their environmental fitness (Chowell et al.,
2017). Driver mutations in Fig. 6A indicated 41%, 19%, and 10% frequency, while B shows only two
driver mutations at 80% and 17%. Results showed that minor subclones can possess greater fitness
than the dominant populations. This experiment suggests minor subclonal populations that possess
driver mutations are often more fit, existing at low frequencies, which may be difficult to detect.
This gives evidence that relapse occurs because small subclonal populations that have high
resistance and low proliferation rate will remain undetected and continue to adapt under drug
therapy until they begin to metastasize (spread) into other tissues.
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Figure 6. Subclonal architecture and differential fitness. (A) & (B). Two simulated subclonal
populations. (C) & (D). The relationship between the number of cells in the subclonal
populations over time. A higher number of minor subclones at a lower frequency can
possess driver mutations that provide higher fitness for the population (Chowell et al.,
2017).
In another study, two gene circuits synthesized from fungus were observed to measure
relative fitness and intratumor heterogeneity (Bodi et al., 2017). The two gene circuits varied in
level of genetic diversity where PF had higher genetic diversity while noPF had lower and were
observed and recorded when placed in increasing levels of fluconazole, an antifungal agent. In Fig. 7,
results revealed higher genetic diversity promoted sustained relative fitness in an environment with
increasing stress levels. These results highlight higher levels of intratumor heterogeneity can have
higher adaptive characteristics that allow for it subclones to survive in large populations.
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Therefore, determining the level of heterogeneity within a tumor is crucial in predicting the success
of pharmaceutical treatments.

Figure 7. Two synthesized gene
circuits. Genetic variability it
high in the PF gene circuit (red)
and low in the noPF gene circuit
(blue). Higher genetic variability
promotes higher levels of
surviving populations (Bodi et
al., 2017).

Evidence of subclonal dynamic offers reason to believe that drug resistance is an
evolutionary process that is built off intratumor heterogeneity. Variations in subclones will
inevitably compete for resources and undergo natural selection or selective sweeps from
traditional drug therapies. Multiregion sequencing offers crucial insight into profiling tumors
accurately for more specific drug treatments and indicates the dynamic diversity within a tumor
that interfere with systemic clinical strategies.
Competition
Intratumor heterogeneity promotes adaptation by selecting for subclones that are more fit
for their environment and results in a competition for resources (Merlo et al., 2006). Elimination of
weaker clones due to starvation or other factors that govern the selective sweeps that will result in
subclonal populations that are more fit to the environment. These factors are built upon the
dynamic between intratumor heterogeneity and the microenvironment as seen in Fig. 4.
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Fluctuations in genetic diversity are due to selective sweeps for advantageous mutations that
promote propagation and survival. Competition among subclonal populations is largely governed
by ecological processes including niche specificity, carrying capacity, and proliferation rate (Bodi et
al., 2017).
Niche specificity. Subclonal relative fitness and survival to the environment, known as
niche specificity, is dependent on hazards, resources, proliferation rate, and carrying capacity of the
environment (Maley et al., 2017). Tumor cell populations will naturally select for mutations with
increased gene expression of proliferation to further develop and sustain larger cell populations
(Bodi et al., 2017). Previously seen in 4C and D, continuous generation of diverse clones will
eventually lead to subclonal populations, which makes it harder for mutational sweeps to cover the
entire neoplasm. This allows for further mutational events that give rise to unique adaptive
characteristics dependent on where the tumor sit in the microenvironment. In the study conducted
by Bodi et al., niche specificity (‘relative fitness’ in Fig. 8), of the two gene circuits was recorded in
increasing concentration of fluconazole (2017). Results in Fig. 8. show the PF gene circuit sustained
high niche specificity longer than the noPF gene circuit. This indicates that surviving populations
and niche specificity are highly dependent on levels of stress in the environment. This also suggests
patients with tumors of high intratumor heterogeneity have an increased risk for therapeutic
tolerance, before treatment even begins. Thus, it is important for researcher to sequence tumor
genomes to predict variability and determine the risk of tolerance to therapy.
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Figure 8. The PF gene circuit (red)
sustained higher levels of fitness
relative to the increasing concentration
of fluconazole compared to the noPF
gene circuit (blue) (Bodi et al., 2017).

Ecological studies modeled the tradeoff between neoplastic proliferation rate and carrying
capacity. If a subclonal population has a high proliferation rate, carrying capacity will increase to
support a larger neoplasm (Gerlee & Anderson, 2015). Reaching carrying capacity will promote
selective sweeps within a population that will knock out weaker variations, promote adaptation,
and further proliferation. The relationship between carrying capacity and proliferation rate is
highly dependent on niche specificity. In ecology, a niche is the position and degree to which an
organism has distinct qualities that allow for it to thrive in the environment. Researchers measured
niche specificity in two tumor samples that varied in its proximity to the subclonal population. In
Fig. 9, ‘spatial’ samples were collected from subclonal cells that were closer in proximity from each
other and ‘well-mixed’ samples were collected from subclonal populations from different regions of
the neoplasm. Results showed ‘well-mixed’ samples had a higher carrying capacity and higher
sustained growth rate when niche specificity increased because it was genetically more variant and
allowed for more advantageous mutations to arise. ‘Spatial’ samples also increased less than the
‘well-mixed’ sample, indicated less diverse populations will not proliferate. This is seen in the
bottom graph where ‘spatial’ samples had much lower growth rates that gradually increased. This
study demonstrates that niche specificity in positively correlated to carrying capacity and growth
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rate and increase with higher genetic diversity. In addition to this, another study injected
metastatic tumor cells into a foreign tumor, which revealed to have stopped the metastasis. This
suggests that subclonal populations with high niche specificity are not able to survive outside of
their microenvironment.

Figure 9. Graphical
representation of carrying
capacity and growth rate as a
function of niche specificity
among two populations that vary
in spatial structure fitness.
‘Spatial’ represents low genetic
diversity, ‘well-mixed’
represents high genetic diversity
(Gerlee & Anderson, 2015).

In the study conducted by Gerlee and Anderson, niche specificity was examined as a
function of carrying capacity and proliferation rate (2015). In Fig. 10, niche specificity (ɣ)
represents the degree of sharing beneficial changes to the environment between cells of the same
spatial location, where ɣ = 0 indicates equal sharing and ɣ =1 has no sharing in the niche due to
maximum cellular density the subpopulation can hold. Fig. 10 shows that in populations with high
specificity (ɣ =1) are less genetically diverse, so proliferation rate will be lower but, has high
carrying capacity for many small subclonal populations. In contrast, subclonal populations with low
niche specificity were found to have higher proliferation rates with lower carrying capacities due to
their larger size. This data shows that the relationship between carrying capacity and proliferation
rate is governed by niche specificity and could provide further insight into drug resistance. This
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suggests the complexity in targeting tumors because resources for one subclonal population may
not be a resource for another.

Figure 10. Graphical
representations carrying
capacity and proliferation rate
under different levels of niche
specificity. As niche specificity
increase, proliferation rate
decreases to increase carrying
capacity (Gerlee & Anderson,
2015).

This evidence shows the stability of the microenvironment plays a major role in tumor
population dynamics. For example, in a stable microenvironment, neoplastic cells are free to
proliferate and expand (Thomas et al., 2012). As a result o clonal expansion, resources become
limited and subclonal populations will compete in which weaker variants will be eliminated and
resistant clones will survive and proliferate. In addition to this, studies have shown that changes in
the microenvironment can also affect the efficacy of drug therapies that target extracellular
pathways including angiogenesis and growth factor pathways (Polyak, Haviv, & Campbell, 2008).
This highlights the difficulty in targeting tissue homeostasis in a niche can trigger chronic
inflammation and wound healing associated with increased risk for cancer. Microenvironments of
tumors pose a significant threat to preventing further neoplastic progression. If there is low stress
or disturbance in the microenvironment, stronger clonal competitors will drive weaker populations
to starvation. These data also suggest that tumors rely more on environmental cues to trigger
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progression, rather than small genetic events, but whether the microenvironment governs clonal
evolution by shaping tumor phenotypes or in response to drug therapies, is still largely debated.
Adaptive therapy. Among the few evolutionary studies that have successfully integrated
cancer’s dynamic mechanisms, Adaptive Therapy (AT) has provided significant success in the
treatment of cancer (Enriquez-Navas, Wojtkowiak, & Gatenby, 2016). Unlike traditional
chemotherapy strategies, AT aims to maximize progression free survival rather than reducing the
systemic strain of cancer. This emphasizes the trade-off between proliferation rate and niche
specificity where by maximizing the survival of tumors that do not progress rather than trying to
reduce all tumors regardless of malignancy. Instead of a fixed dose and drug schedule, AT also
features dynamic administration which exploits tumor evolutionary dynamic by constantly
adjusting minimal dosing to maintain a stable tumor environment and increase quality of life. Once
the tumor is stabilized, therapy is then reduced or withheld to reduce the risk of aggravating the
tumor. Weaker variations are able to survive and grow at the resistant cells expense. The main goal
of AT is to administer the absolute minimum dose necessary to maintain a stable tumor
environment that lowers the risk of developing drug resistance or relapse.
GAPS
Major clinical gaps in evolutionary models of cancer comes from the concerningly low
quantity of relevant studies conducted in recent years. Cross examination of research articles
gathered since 1915, revealed the limited extent to which evolutionary models have been clinically
adopted (Aktipis et al., 2011). This investigation led researchers to 6,628 drug resistance research
articles with abstracts that contain evolutionary terms. From the data in Fig. 11, evolutionary terms
in abstracts peaked in 1983 and had several significant drops between 1984-1990. A steady rise in
evolutionary terms in abstracts gradually arose but remained at a very low frequency. Before 1983,
there was no evidence of evolutionary terms in abstracts in research articles on drug resistance. Of
the same 6,228 research articles, proportions of evolutionary terms were measured in the
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abstracts. In Fig. 12, results showed that ‘evolution’ was used most frequently and ‘natural
selection’ was not found in any of the articles abstracts (Aktipis et al., 2011). This suggests that of
the relevant evolutionary cancer papers, most fail to investigate natural selection, and clonal
expansion, two key principles in tumor evolution and drug resistance.
In a second study of the same experiment, 10 of the most recent papers from PubMed, ISI,
and Medline databases, were selected to contain terms like ‘therapeutic resistance’ or ‘relapse’ in
the title, and ‘cancer’ in the abstract (Aktipis et al., 2011). After these filters were applied, 22
distinct papers were selected. Fig. 13 reveals from these articles, only two used ‘evolution’ to
explain resistant, and six had no explanation for resistance at all. This reveals that researchers have
been unable to explain drug resistance in evolutionary terms. This helps confirm that there is little
clinical cancer research being conducted using evolutionary modeling. Additionally, among the 22
articles, evolutionary studies on drug resistance were found to largely investigate between-patient
heterogeneity. Leaving intratumor heterogeneity disproportionately uninvestigated, this reveals
another significant gap in the research. Fig. 14 shows heterogeneity studies defined and recorded
by the measurement (between patient vs. within tumor). Of the seven studies that focused on
intratumor heterogeneity, only two investigated epigenetic determinants. These studies highlight
foundational gaps in evolutionary cancer modeling that interfere with clinical integration.

Figure 11. Frequency of
evolutionary terms used in
abstracts beginning in 1983 and
lower proportions leading into
the 2000’s (Aktipis et al., 2011).
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Figure 12. Frequency of evolutionary
terms in abstracts of relapse studies
since 1915. Out of 6,228 papers,
‘natural selection’ was not present in
any of the abstracts (Aktipis et al.,
2011).

Figure 13. Frequencies of explanations
of drug resistance in 22 relevant
articles. Only two papers used
evolution as an explanation for
resistance and six had no explanation
(Aktipis et al., 2011).

Figure 14. Types of evolutionary
studies conducted leaning heavily
toward between patient
heterogeneity. Significant lack of
intratumor heterogeneity studies
(Aktipis et al., 2011).

Gaps identified from the research include low quantity of evolutionary studies,
disproportionate studies that focus on intratumor heterogeneity, and absence of studies that use
natural selection to explain drug resistance.
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PROBLEM ANALYSIS
Historical perspective. The first proposal of cancer as an evolutionary process only
recently came into existence in 1976 by cancer researcher, Peter Nowell. The drop offs in certain
years including during 1984-1990 may be due to the field being in its infancy stage and other
trends in scientific research including AIDS. Another historical event that could have triggered
more consistent research starting in 1990 when the Human Genome Project was launched, to map
out the 30,000 genes in the human genome. This research can also explain the drop off in 2004,
because the project was completed in 2003, two years earlier than the expected completion date.
Lack of technology. Another major challenge in studying evolution of cancer is the
limitations in tools and technology for integrating into clinical use. (Aktipis et al., 2011). In the
1960’s, Peter Nowell developed a theory for carcinogenic evolution developed by strong evidence
of sequential accumulation of genetic alterations that were observed by cytological staining of
chromosomes. Despite Nowell’s theory, recent research has primarily focused on molecular biology
assays that measure homogenization (fixation) of cancer tissues to measure protein, RNA, and DNA
values. This is problematic for determining adaptive mechanisms of cancer because by stabilizing
the neoplastic tissues, adaptive evolution of heterogeneity cannot be examined accurately. In
addition to this, cross-sectional designs constitute most neoplasm studies, because most neoplasms
are resected upon detection, making it clinically impossible to observe and collect data over time.
Risk Aversion. Most neoplastic studies are cross-sectional designs, because when a
neoplasm is detected, clinicians strive to reduce immediate strain of the cancer by removing the
source. Risk aversion carries significant consequences to integrating evolutionary modeling for
clinical strategies. One study revealed benign tumors are prematurely removed because clinicians
and patients do not want to risk the chance of it developing malignancy, even with a low probability
(Aktipis et al., 2011). In contrast, another study found that clinicians were unwilling to collect
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posttherapy biopsies, as it would be an unnecessary invasive procedure with no direct advantage
for
the patient and could increase the risk of relapse. A survey study found medical oncologists (MO)
and Institutional Review Board (IRB) members were less willing to accept higher risks and
overestimated patient’s degree of invoked biopsy sampling-anxiety (Agulnik, Oza, & Siu, 2014). In
contrast, another survey recorded responses and confirmed a general desire among physicians to
collect tumor biopsies samples for further research, while 31% of IRBs suggested the destruction of
tumor biopsies. This conflicts with both MOs and patient’s wishes, but also questions the current
ethical function of the IRB. Results from the surveys are represented in bar graphs in Fig. 15, where
major complication, pain, infection, and bleeding were assessed as potential risks. Surveys were
administered to different groups including trial and clinic patients, MOs, and IRB members to
measure the amount of acceptable risk within the types of risks. Results shows IRBs had
significantly lower acceptable risk across all conditions. MOs were also much lower in all risk
conditions except for pain. This raises an interesting ethical standpoint on different types of risk. A
compelling notion is that of the risk condition, pain has the highest acceptable risk of all groups.
Low MO and IRBs scores may be due to legal implications that arise from major complications.
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Figure 15. Scores of acceptable risk among trial and clinical patients, MOs (medical
oncologists), and IRB (Institutional review board) members. Survey measured different
types of risk in categories of major complication, pain, infection, and bleeding. Results show
MOs and IRBs had much lower acceptable risk than both patient groups (Agulnik et al.,
2014).
Psychological gaps. Lack of fostering evolutionary thinking at the institutional and
education level contributes to the delay in evolutionary models for cancer (Aktipis et al., 2011).
Despite general acknowledgment and compelling evidence of evolutionary disease progression,
common misconceptions may also contribute to the gaps of knowledge in neoplastic evolution.
Medical research at its core, relies on finding fundamental patterns in disease, to which they use to
target and treat. However, tumors are not singular, nor fixed; they are populations of genetically
diverse cells with varying ability to proliferate and survive. Relying on core patterns of disease fails
to recognize heterogeneity and the dynamic adaptation of cancer (Aktipis, Maley, & Neuberg, 2010).
Common psychological phenomenon’s that are present in clinical strategies for cancer treatment
include risk aversion results in overtreatment and lack of biopsy studies as previously depicted in
Fig. 15. This evidence suggests that by accepting folk wisdom of “better safe than sorry” thinking is
a result of highlighting the overall risk of developing cancer, rather than analyzing and considering
the risks of intervention that can impact cancer’s evolutionary dynamic. Clinicians tendency to
essentialize disease, leads to failure in understanding and accepting robust evolutionary models of
cancer progression and ultimately interfering with progress in treatment strategies. Systemic
treatment, premature resection of premalignant tumors, and unwillingness to collect post-therapy
biopsies are the consequences of neglecting the dynamic of neoplastic progression
BROADER IMPLICATIONS
Despite the growing body of evidence for evolutionary modeling and tools for studying
neoplastic progression, clinical development bypassing drug resistance remains elusive. Delay in
using evolutionary theory for clinical application is largely attributed to the complexities of the
dynamic tumor evolution, driven by intratumor heterogeneity, lack of robust evolutionary tools and
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data, and the misconception of cancer as a static and unitary entity. Investigating the dynamic
interactions between adaptive mechanisms of cancer can provide valuable insight into predicting
cancer progression, as well as future research for personalized medicine. Without understanding
cancer as a deeply evolutionary process, therapeutic strategies will continue to be bypassed by
drug resistant tumors. In other words, failure to integrate evolutionary thinking into drug
resistance will continue to interfere with developing robust approaches. Adaptive therapy is a
crucial step forward in integrating evolutionary cancer dynamics to clinical strategies. By exploiting
tumor evolution dynamics, constantly adjusting minimal dose administration aims to maintain a
stable tumor environment where proliferation and mutation are kept at a minimum. By doing this,
the patient is exempt from undergoing harmful chemotherapy drug schedules and high doses and
will significantly improve quality of life. Not only this, but cost effectiveness is seen in targeting
cancer with minimal doses that are aimed to maintain the stability of the tumor and its
microenvironment.
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